JP5721949B2 - 複合薬剤 - Google Patents

複合薬剤 Download PDF

Info

Publication number
JP5721949B2
JP5721949B2 JP2009531913A JP2009531913A JP5721949B2 JP 5721949 B2 JP5721949 B2 JP 5721949B2 JP 2009531913 A JP2009531913 A JP 2009531913A JP 2009531913 A JP2009531913 A JP 2009531913A JP 5721949 B2 JP5721949 B2 JP 5721949B2
Authority
JP
Japan
Prior art keywords
isopropyl
dihydroxy
dihydro
phenyl
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009531913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505928A5 (enExample
JP2010505928A (ja
Inventor
ニール、ジェームス、ギャラガー
ジョン、フランシス、ライアンズ
ニール、トーマス、トンプソン
スティーブン、マレー、ユール
クリストファー、ウィリアム、マレー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of JP2010505928A publication Critical patent/JP2010505928A/ja
Publication of JP2010505928A5 publication Critical patent/JP2010505928A5/ja
Application granted granted Critical
Publication of JP5721949B2 publication Critical patent/JP5721949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2009531913A 2006-10-12 2007-10-12 複合薬剤 Active JP5721949B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82921506P 2006-10-12 2006-10-12
US82921306P 2006-10-12 2006-10-12
US60/829,215 2006-10-12
US60/829,213 2006-10-12
PCT/GB2007/003864 WO2008044029A1 (en) 2006-10-12 2007-10-12 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
JP2010505928A JP2010505928A (ja) 2010-02-25
JP2010505928A5 JP2010505928A5 (enExample) 2011-12-22
JP5721949B2 true JP5721949B2 (ja) 2015-05-20

Family

ID=39027649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531913A Active JP5721949B2 (ja) 2006-10-12 2007-10-12 複合薬剤

Country Status (4)

Country Link
US (1) US8277807B2 (enExample)
EP (1) EP2073802A1 (enExample)
JP (1) JP5721949B2 (enExample)
WO (1) WO2008044029A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
JP5518478B2 (ja) * 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8883790B2 (en) * 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
JP5410285B2 (ja) * 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010018481A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. 2-amino pyrimidine compounds as potent hsp-90 inhibitors
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
GB201009853D0 (en) 2010-06-11 2010-07-21 Chroma Therapeutics Ltd HSP90 inhibitors
BR112013027448A2 (pt) * 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
CN115778934A (zh) 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
CA2864118A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
EP3738594A1 (en) * 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
US20180169117A1 (en) * 2014-03-20 2018-06-21 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical formulation comprising a substituted phenyl - (1,3-dihydro-isoindol-2-yl) - methanone
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
AU2017257153A1 (en) 2016-04-29 2018-11-22 Board Of Regents, The University Of Texas System Sigma receptor binders
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CA3232086A1 (en) * 2021-10-15 2023-04-20 Peter Jarrett Prodrugs of axitinib

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4910506A (enExample) 1972-05-31 1974-01-30
US4582909A (en) 1984-02-02 1986-04-15 Warner-Lambert Company Benzobicyclic lactam acids and derivatives as cognition activators
US4760064A (en) 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
CA1340191C (en) 1988-06-13 1998-12-15 Katsuhiro Imaki Derivatives of p-substituted phenyl ester of pivalic acid
US4990511A (en) 1988-08-03 1991-02-05 Takeda Chemical Industries, Ltd. Amide compounds, their production and use
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5124350A (en) 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
CA2049481A1 (en) 1990-08-27 1992-02-28 Jill Ann Panetta Method of treating inflammatory bowel disease
FR2669029B1 (fr) 1990-11-14 1994-09-02 Adir Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
WO1992017467A1 (en) 1991-04-06 1992-10-15 Dr Lo. Zambeletti S.P.A. Substituted azacyclic compounds, process for their preparation and their use as analgesics
US5633283A (en) 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JP3855026B2 (ja) 1996-01-16 2006-12-06 富士レビオ株式会社 アミド誘導体の製造方法
ATE478672T1 (de) 1996-01-29 2010-09-15 Univ California Methode zur behandlung sexueller fehlfunktionen
GB9606187D0 (en) 1996-03-23 1996-05-29 Inst Of Food Research Production of vanillin
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
EP0918518A4 (en) 1996-04-19 2002-05-02 Univ California TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS.
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US6166008A (en) 1997-10-27 2000-12-26 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
EP1165492A1 (en) 1999-03-30 2002-01-02 Pharmacor Inc. Hydroxyphenyl derivatives with hiv integrase inhibitory properties
DE19955283A1 (de) 1999-11-17 2001-05-23 Aventis Res & Tech Gmbh & Co Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
AU2001243158A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
JP2004507456A (ja) 2000-05-11 2004-03-11 ブリストル−マイヤーズ　スクイブ　カンパニー 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
AP2001002249A0 (en) 2000-08-25 2001-09-30 Warner Lambert Co Process for making N-ARYL-ANTHRANILIC acids and their derivatives.
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
AU2002366362A1 (en) 2001-12-18 2003-06-30 Bayer Aktiengesellschaft 2-substituted pyrrolo(2.1-a)isoquinolines against cancer
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
EP1497268A4 (en) 2002-04-05 2006-01-18 Nitromed Inc NITROGEN OXIDE DISPENSER, COMPOSITIONS AND METHOD OF USE
EA009523B1 (ru) 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
CA2488342A1 (en) 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
AU2003242103A1 (en) 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CN100354276C (zh) 2002-07-16 2007-12-12 阿姆拉医疗有限公司 生物活性化合物
JP2006505571A (ja) 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
TWI228885B (en) * 2003-01-23 2005-03-01 Mediatek Inc Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode
KR101166749B1 (ko) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
JP2006514088A (ja) 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−２−マクログロブリンを含む組成物の使用方法
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
AU2004234067B2 (en) 2003-04-30 2008-02-28 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
AU2004251949B2 (en) 2003-06-27 2009-05-07 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
TWI322806B (en) 2003-06-30 2010-04-01 Mitsubishi Tanabe Pharma Corp Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
RU2396250C2 (ru) 2003-07-24 2010-08-10 Лео Фарма А/С Новые производные аминобензофенона
WO2005012296A1 (en) 2003-07-28 2005-02-10 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
DE10335584B4 (de) 2003-07-31 2006-06-29 Philipps-Universität Marburg Verfahren zur Herstellung zyklischer Moleküle
DE10335726A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener
WO2005016889A1 (en) 2003-08-08 2005-02-24 Virginia Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
CN1902171A (zh) 2003-11-10 2007-01-24 舍林股份公司 用作ccr－5拮抗剂的苄醚胺化合物
EP1704856A4 (en) 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
BRPI0514504A (pt) 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
US7781485B2 (en) 2004-11-09 2010-08-24 Kyowa Hakko Kirin Co., Ltd. Hsp90 family protein inhibitors
WO2006082001A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
WO2006088954A1 (en) 2005-02-15 2006-08-24 Janssen Pharmaceutica, N.V. Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
JPWO2006088193A1 (ja) 2005-02-21 2008-07-03 協和醗酵工業株式会社 抗腫瘍剤
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
US7425633B2 (en) * 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones

Also Published As

Publication number Publication date
US20100092474A1 (en) 2010-04-15
US8277807B2 (en) 2012-10-02
WO2008044029A1 (en) 2008-04-17
JP2010505928A (ja) 2010-02-25
EP2073802A1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
JP5528806B2 (ja) 複合薬剤
JP5528807B2 (ja) 複合薬剤
US8277807B2 (en) Pharmaceutical combinations
US20090142337A1 (en) Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
JP5523829B2 (ja) 複合薬剤
US20110159111A1 (en) Pharmaceutical combinations
JP2009536620A (ja) 医薬組み合わせ物
JP5518478B2 (ja) 医薬化合物
JP2009543770A (ja) Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
MX2007008809A (es) Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor.
JP5345842B2 (ja) プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
EP3119398A1 (en) Pharmaceutical formulation comprising a substitued phenyl- (1, 3-dihydro-isoindol-2-yl) -methanone
CN101484173A (zh) Pk抑制剂与其他活性药的药物组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20130104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150325

R150 Certificate of patent or registration of utility model

Ref document number: 5721949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250